Cholangiocarcinoma is a heterogeneous group of biliary tract cancers that has a poor prognosis and globally increasing incidence and mortality. While surgical resection remains the only curative option for the treatment of cholangiocarcinoma, the majority of cancers are unresectable at the time of diagnosis. Additionally, the prognosis of cholangiocarcinoma remains poor even with the current first-line systemic therapy regimens, highlighting the difficulty of treating locally advanced, metastatic, or unresectable cholangiocarcinoma. Through recent developments, targetable oncogenic driver mutations have been identified in the pathogenesis of cholangiocarcinoma, leading to the utilization of molecular targeted therapeutics. In this review, we comprehensively discuss the latest molecular therapeutics for the treatment of cholangiocarcinoma, including emerging immunotherapies, highlighting promising developments and strategies.
胆管癌是一组异质性胆道恶性肿瘤，预后不良，全球发病率和死亡率持续上升。虽然手术切除仍是目前唯一可能治愈胆管癌的治疗手段，但多数患者在确诊时已失去手术机会。此外，即使采用当前一线全身治疗方案，胆管癌的预后仍然较差，这凸显了治疗局部晚期、转移性或不可切除胆管癌的临床困境。随着近期研究进展，已在胆管癌发病机制中发现多种可靶向的致癌驱动基因突变，推动了分子靶向治疗的应用。本综述系统探讨胆管癌治疗领域的最新分子疗法，包括新兴免疫治疗方案，重点阐述具有临床应用前景的治疗进展与策略。
肿瘤(癌症)患者之家